Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis

被引:9
作者
Twiner, Michael J. [1 ]
Marinica, Alexander L. [7 ]
Kuper, Kenneth [8 ]
Goodman, Allen [2 ]
Mahn, James J. [3 ]
Burla, Michael J. [1 ,11 ]
Brody, Aaron M. [1 ]
Carroll, Justin A. [3 ,12 ]
Willock, Robina Josiah [9 ]
Flack, John M. [4 ,5 ,6 ]
Nasser, Samar A. [10 ]
Levy, Phillip D. [6 ]
机构
[1] Wayne State Univ, Dept Emergency Med, Detroit, MI USA
[2] Wayne State Univ, Dept Econ, Detroit, MI USA
[3] Wayne State Univ, Sch Med, Detroit, MI USA
[4] Wayne State Univ, Div Transit Res & Clin Epidemiol, Detroit, MI USA
[5] Wayne State Univ, Dept Med, Detroit, MI 48202 USA
[6] Wayne State Univ, Cardiovasc Res Inst, Detroit, MI 48202 USA
[7] Sinai Grace Hosp, Dept Surg, Detroit, MI USA
[8] St Johns Hosp, Dept Emergency Med, Detroit, MI USA
[9] Morehouse Sch Med, Community Hlth & Prevent Med, Atlanta, GA 30310 USA
[10] Univ Michigan, Coll Educ Hlth & Human Serv, Dearborn, MI 48128 USA
[11] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA
[12] Ohio State Univ, Dept Emergency Med, Coll Med, Columbus, OH 43210 USA
关键词
LEFT-VENTRICULAR HYPERTROPHY; UNITED-STATES ADULTS; SYSTOLIC DYSFUNCTION; NATRIURETIC PEPTIDE; AFRICAN-AMERICANS; HEALTH-STATUS; PREVALENCE; FAILURE; AWARENESS; PREVENTION;
D O I
10.1111/acem.13122
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
ObjectivesPoorly controlled hypertension (HTN) is extremely prevalent and, if left unchecked, subclinical hypertensive heart disease (SHHD) may ensue leading to conditions such as heart failure. To address this, we designed a multidisciplinary program to detect and treat SHHD in a high-risk, predominantly African American community. The primary objective of this study was to determine the cost-effectiveness of our program. MethodsStudy costs associated with identifying and treating patients with SHHD were calculated and a sensitivity analysis was performed comparing the effect of four parameters on cost estimates. These included prevalence of disease, effectiveness of treatment (regression of SHHD, reversal of left ventricular hypertrophy [LVH], or blood pressure [BP] control as separate measures), echocardiogram costs, and participant time/travel costs. The parent study for this analysis was a single-center, randomized controlled trial comparing cardiac effects of standard and intense (<120/80 mm Hg) BP goals at 1 year in patients with uncontrolled HTN and SHHD. A total of 149 patients (94% African American) were enrolled, 133 (89%) had SHHD, 123 (93%) of whom were randomized, with 88 (72%) completing the study. Patients were clinically evaluated and medically managed over the course of 1 year with repeated echocardiograms. Costs of these interventions were analyzed and, following standard practices, a cost per quality-adjusted life-year (QALY) less than $50,000 was defined as cost-effective. ResultsTotal costs estimates for the program ranged from $117,044 to $119,319. Cost per QALY was dependent on SHHD prevalence and the measure of effectiveness but not input costs. Cost-effectiveness (cost per QALY less than $50,000) was achieved when SHHD prevalence exceeded 11.1% for regression of SHHD, 4.7% for reversal of LVH, and 2.9% for achievement of BP control. ConclusionsIn this cohort of predominantly African American patients with uncontrolled HTN, SHHD prevalence was high and screening with treatment was cost-effective across a range of assumptions. These data suggest that multidisciplinary programs such as this can be a cost-effective mechanism to mitigate the cardiovascular consequences of HTN in emergency department patients with uncontrolled BP.
引用
收藏
页码:168 / 176
页数:9
相关论文
共 50 条
  • [41] Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area
    Li, Jun
    Yip, Benjamin H. K.
    Leung, Chichiu
    Chung, Wankyo
    Kwok, Kin On
    Chan, Emily Y. Y.
    Yeoh, Engkiong
    Chung, Puihong
    [J]. PLOS ONE, 2018, 13 (01):
  • [42] Incremental cost-effectiveness analysis of a multidisciplinary renal education program for patients with chronic renal disease
    Sabariego, Carla
    Grill, Eva
    Brach, Mirjam
    Fritschka, Emanuel
    Mahlmeister, Jarmila
    Stucki, Gerold
    [J]. DISABILITY AND REHABILITATION, 2010, 32 (05) : 392 - 401
  • [43] Cost-Effectiveness Analysis of Natriuretic Peptide Testing and Specialist Management in Patients with Suspected Acute Heart Failure
    Griffin, Edward A.
    Wonderling, David
    Ludman, Andrew J.
    Al-Mohammad, Abdallah
    Cowie, Martin R.
    Hardman, Suzanna M. C.
    McMurray, John J. V.
    Kendall, Jason
    Mitchell, Polly
    Shote, Aminat
    Dworzynski, Katharina
    Mant, Jonathan
    [J]. VALUE IN HEALTH, 2017, 20 (08) : 1025 - 1033
  • [44] Using Stress Testing to Guide Primary Prevention of Coronary Heart Disease Among Intermediate-Risk Patients A Cost-Effectiveness Analysis
    Galper, Benjamin Z.
    Moran, Andrew
    Coxson, Pamela G.
    Pletcher, Mark J.
    Heidenreich, Paul
    Lazar, Lawrence D.
    Rodondi, Nicolas
    Wang, Y. Claire
    Goldman, Lee
    [J]. CIRCULATION, 2012, 125 (02) : 260 - U205
  • [45] Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder
    Leong, Randall K.
    de Wachter, Stephan G. G.
    Joore, Manuela A.
    van Kerrebroeck, Philip E. V.
    [J]. BJU INTERNATIONAL, 2011, 108 (04) : 558 - 564
  • [46] Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction
    Tan, Yi Jing
    Linden, Stephan
    Ong, Siew Chin
    [J]. PLOS ONE, 2024, 19 (08):
  • [47] Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis
    Glasziou, Paul P.
    Clarke, Philip
    Alexander, Jan
    Rajmokan, Mohana
    Beller, Elaine
    Woodward, Mark
    Chalmers, John
    Poulter, Neil
    Patel, Anushka
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2010, 193 (06) : 320 - 324
  • [48] Cost-Effectiveness Analysis of Screening for Hepatitis B Virus Infection in Patients With Solid Tumors Before Initiating Chemotherapy
    Konijeti, Gauree G.
    Grandhe, Sirisha
    Tincopa, Monica
    Lane, Jill A.
    Shrime, Mark G.
    Singh, Siddharth
    Loomba, Rohit
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (07) : 1600 - +
  • [49] Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom
    Williams, Jack
    Vickerman, Peter
    Smout, Elizabeth
    Page, Emma E.
    Phyu, Khine
    Aldersley, Mark
    Nebbia, Gaia
    Douthwaite, Sam
    Hunter, Laura
    Ruf, Murad
    Miners, Alec
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
  • [50] COST-EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH NYHA I AND NYHA II HEART FAILURE IN SPAIN
    Almenar, Luis
    Diaz, Beatriz
    Quesada, Aurelio
    Crespo, Carlos
    Marti, Belen
    Mealing, Stuart
    Linde, Cecilia
    Daubert, Claude
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2013, 29 (02) : 140 - 146